We conducted univariate analysis to evaluate the effects on survival of variables including age, sex, race/ethnicity, ECOG performance status, tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigens [CAs] CA 19-9, CA 125, CA 27.29); history of thromboembolism; number of prior therapies; presence of liver metastases; number of metastatic sites; leukocyte count; hemoglobin level; platelet count; and albumin, lactate dehydrogenase (LDH), alkaline phosphatase, bilirubin, alanine aminotransferase, aspartate aminotransferase, RMH score and serum creatinine levels (Table 2). The gene discussed is ALB; the disease is Thromboembolism.